About: JNJ-Q2

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed. As of 2016, tests are ongoing.

Property	Value
dbo:abstract	JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed. As of 2016, tests are ongoing. (en)
dbo:casNumber	878592-87-1
dbo:fdaUniiCode	070SV15RJA
dbo:thumbnail	wiki-commons:Special:FilePath/JNJ-Q2.svg?width=300
dbo:wikiPageID	36867195 (xsd:integer)
dbo:wikiPageLength	3711 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1073797761 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Methicillin-resistant_Staphylococcus_aureus dbr:Johnson_&_Johnson dbc:Cyclopropanes dbc:Piperidines dbr:Fluoroquinolone dbr:Janssen_Pharmaceutica dbc:Fluoroquinolone_antibiotics dbr:Pneumonia dbr:Antibacterial dbr:Skin
dbp:c	21 (xsd:integer)
dbp:casNumber	878592 (xsd:integer)
dbp:chemspiderid	9721013 (xsd:integer)
dbp:f	2 (xsd:integer)
dbp:h	23 (xsd:integer)
dbp:iupacName	7 (xsd:integer)
dbp:n	3 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:routesOfAdministration	Oral, IV (en)
dbp:smiles	Fc1cN4C/CCCC4 (en)
dbp:stdinchi	InChI=1S/C21H23F2N3O4/c1-30-20-17-137-151825-6-2-3-11168-24/h7,10,12H,2-6,8-9,24H2,1H3,/b16-11+ (en)
dbp:stdinchikey	VMKVDAAFMQKZJS-LFIBNONCSA-N (en)
dbp:unii	70 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Antibiotic-stub dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:QuinoloneAntiBiotics
dct:subject	dbc:Cyclopropanes dbc:Piperidines dbc:Fluoroquinolone_antibiotics
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatCyclopropanes yago:Agent114778436 yago:Anesthetic102710766 yago:Antibacterial102716205 yago:Antibiotic102716866 yago:CausalAgent100007347 yago:Cyclopropane103155661 yago:Drug103247620 yago:GeneralAnesthetic103433434 yago:InhalationAnesthetic103570838 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:WikicatFluoroquinoloneAntibiotics
rdfs:comment	JNJ-Q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Specifically, JNJ-Q2 is being actively studied for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Furiex Pharmaceuticals has licensed JNJ-Q2 from Janssen Pharmaceutica, a unit of Johnson & Johnson, which discovered JNJ-Q2. Furiex is responsible for its development and commercialization. Both oral and intravenous formulations are being developed. As of 2016, tests are ongoing. (en)
rdfs:label	JNJ-Q2 (en)
owl:sameAs	freebase:JNJ-Q2 yago-res:JNJ-Q2 wikidata:JNJ-Q2 dbpedia-fa:JNJ-Q2 dbpedia-sh:JNJ-Q2 dbpedia-sr:JNJ-Q2 https://global.dbpedia.org/id/4oEq2
prov:wasDerivedFrom	wikipedia-en:JNJ-Q2?oldid=1073797761&ns=0
foaf:depiction	wiki-commons:Special:FilePath/JNJ-Q2.svg
foaf:isPrimaryTopicOf	wikipedia-en:JNJ-Q2
is foaf:primaryTopic of	wikipedia-en:JNJ-Q2